全文获取类型
收费全文 | 436篇 |
免费 | 27篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 3篇 |
妇产科学 | 21篇 |
基础医学 | 61篇 |
口腔科学 | 4篇 |
临床医学 | 19篇 |
内科学 | 122篇 |
神经病学 | 20篇 |
特种医学 | 67篇 |
外科学 | 54篇 |
综合类 | 6篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 9篇 |
肿瘤学 | 79篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 7篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 14篇 |
2017年 | 6篇 |
2016年 | 16篇 |
2015年 | 19篇 |
2014年 | 13篇 |
2013年 | 26篇 |
2012年 | 34篇 |
2011年 | 31篇 |
2010年 | 20篇 |
2009年 | 9篇 |
2008年 | 20篇 |
2007年 | 32篇 |
2006年 | 32篇 |
2005年 | 20篇 |
2004年 | 26篇 |
2003年 | 20篇 |
2002年 | 20篇 |
2001年 | 11篇 |
2000年 | 9篇 |
1999年 | 14篇 |
1998年 | 5篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1994年 | 4篇 |
1993年 | 7篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 1篇 |
1989年 | 5篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1971年 | 2篇 |
排序方式: 共有469条查询结果,搜索用时 328 毫秒
1.
David J. Seiffge MD Gian Marco De Marchis MD Masatoshi Koga MD PhD Maurizio Paciaroni MD Duncan Wilson PhD Manuel Cappellari MD Kosmas Macha MD Georgios Tsivgoulis MD Gareth Ambler PhD Shoji Arihiro MD Leo H. Bonati MD Bruno Bonetti MD Bernd Kallmünzer MD Keith W. Muir MD PhD Paolo Bovi MD Henrik Gensicke MD Manabu Inoue MD Stefan Schwab MD Shadi Yaghi MD Martin M. Brown MD PhD FRCP Philippe Lyrer MD Masahito Takagi MD PhD Monica Acciarrese MD Hans Rolf Jager MD FRCP Alexandros A. Polymeris MD Kazunori Toyoda MD PhD Michele Venti MD Christopher Traenka MD Hiroshi Yamagami MD PhD Andrea Alberti MD Sohei Yoshimura MD PhD Valeria Caso MD Stefan T. Engelter MD David J. Werring MD PhD FRCP the RAF RAF-DOAC CROMIS- SAMURAI NOACISP Erlangen and Verona registry collaborators 《Annals of neurology》2020,87(5):677-687
2.
3.
4.
5.
Matsubara R Kawano S Chikui T Kiyosue T Goto Y Hirano M Jinno T Nagata T Oobu K Abe K Nakamura S 《Academic radiology》2012,19(6):708-717
6.
Daisuke Ban Atsushi Kudo Takumi Irie Takanori Ochiai Arihiro Aihara Satoshi Matsumura Shinji Tanaka Minoru Tanabe 《Asian journal of endoscopic surgery》2015,8(1):11-15
Reduced port surgery has been attracting attention in the field of minimally invasive surgery. Although the use of SILS is becoming widespread, technical difficulty has delayed its adoption for laparoscopic liver resection. Recently, advances in laparoscopic liver resection have been made in tandem with advances in surgical skill and devices. The main driver in conventional laparoscopic liver resection's evolution to become less surgically invasive seems to be single‐incision laparoscopic liver resection (SILLR). To date, most reports on SILLR have been single case reports or case series. Only a few cohort studies on conventional laparoscopic surgery and SILLR have been conducted. Recent reports have described the use of SILLR for well‐localized lesions and solitary tumors located in the anterolateral segments of the liver or left liver lobe, but its application remains limited to partial resection and left lateral sectionectomy. The feasibility and safety of SILLR have been demonstrated, but additional work is needed for standardization of the procedure. 相似文献
7.
8.
Tomoki Kobayashi Hiroshi Aikata Tsuyoshi Kobayashi Hideki Ohdan Koji Arihiro Kazuaki Chayama 《Hepatobiliary & pancreatic diseases international : HBPD INT》2017,16(3):279-288
BACKGROUND: Early recurrence(ER) after hepatic resection(HR) is a poor prognostic factor for patients with hepatocellular carcinoma(HCC). This study aimed to identify the clinicopathological features, outcomes, and risk factors for ER after HR for small HCC in order to clarify the reasons why ER is a worse recurrence pattern.METHODS: We retrospectively examined 130 patients who underwent HR for small HCC(≤30 mm). Recurrence was classified into ER(2 years) and late recurrence(LR)(≥2 years). The clinicopathological features, outcomes, and risk factors for ER were analyzed by multivariate analysis.RESULTS: ER was observed in 39 patients(30.0%). The survival rate of the ER group was significantly lower than that of the LR group(P0.005), and ER was an independent prognostic factor for poor survival(P=0.0001). The ER group had a significantly higher frequency(P=0.0039) and shorter interval(P=0.027) of development to carcinoma beyond the Milan criteria(DBMC) compared with the LR group, and ER was an independent risk factor for DBMC(P0.0001). Multi-nodularity, non-simple nodular type, and microvascular invasion were independent predictors for ER(P=0.012, 0.010, and 0.019, respectively).CONCLUSIONS: ER was a highly malignant recurrence pattern associated with DBMC and subsequent poor survival after HR for small HCC. Multi-nodularity, non-simple nodular type, and microvascular invasion predict ER, and taking these factors into consideration may be useful for the decision of the treatment strategy for small HCC after HR. 相似文献
9.
10.
Daisaku Masuda Arihiro Kiyosue Atsushi Hirayama Junichiro Shimauchi J. Antonio G. Lpez Kazumasa Miyawaki Shizuya Yamashita 《Journal of atherosclerosis and thrombosis》2020,27(11):1183
Aims: Profiling of lipoproteins can predict risk of cardiovascular disease; gel permeation high-performance liquid chromatography (HPLC) improves prediction accuracy by providing detailed data for specific lipoprotein subclasses. This study applied HPLC to examine the effects of evolocumab, which effectively treats hyperlipidemia and mixed dyslipidemia, on lipoprotein subclasses, specifically the number and size of lipoprotein particles.Methods: This post-hoc analysis used patient blood samples from YUKAWA-2, a phase 3 trial evaluating the efficacy of evolocumab in Japanese adult patients with hyperlipidemia or mixed dyslipidemia and at high risk for cardiovascular disease. We used HPLC to assess observed values and percent change from baseline in cholesterol and triglyceride (TG) concentrations, number of particles in lipoprotein subclasses to week 12, and mean observed values and mean percent change from baseline in variables to weeks 10 and 12. HPLC was also compared with conventional methods in assessing low-density lipoprotein (LDL) cholesterol (LDL-C) values.Results: Data for all 404 patients were analyzed. Evolocumab significantly decreased cholesterol and TG concentrations, and total particle count, in very low-density lipoprotein (VLDL) and LDL subclasses. Particle size increased slightly in LDL, high-density lipoprotein (HDL), and VLDL, but data varied widely. At very low L-DLC, HPLC measurements were higher than those from conventional methods.Conclusion: This research used HPLC to assess the effects of evolocumab in 20 lipid subclasses. By lowering lipid content and improving the lipid profile, evolocumab may reduce atherogenicity. This reduction is better quantified by HPLC than by conventional methods in the very low LDL-C range. 相似文献